CONNECT WITH US
HealthTech

HealthTech

Antibody-drug conjugate shows promising early results in Phase I trial in sarcoma patients

Medical Xpress logo

Published on

Add as a preferred source on Google
Antibody-drug conjugate shows promising early results in Phase I trial in sarcoma patients

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a Trojan Horse, has shown promising early results across diverse types of soft tissue sarcoma in a Phase I trial. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Soft tissue sarcomas develop in the body's connective tissues, such as fat, muscle, blood vessels and nerves. There are more than 100 different subtypes of sarcoma, and they can affect people of any age. If the disease spreads to other parts of the body, the outcome for patients is extremely poor, with fewer than one in five patients alive five years after diagnosis. Current treatment options are very limited and there is a clear and urgent need for better treatments.

The early trial results were presented by Patrick Schöffski, Head of the Department of General Medical Oncology at the University Hospitals Leuven and Professor in the Department of Oncology at KU Leuven, Belgium. He said, "Antibody-drug conjugates, or ADCs, have changed the treatment of several common malignancies, such as breast cancer, but none have been approved for soft tissue sarcomas. In this trial we are working with an ADC called ADCE-D01 that targets a protein called uPARAP.

"Our research has shown that this protein is found at high levels in the majority of sarcoma subtypes.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.